Compare Avient Corporation (AVNT) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avient Corporation vs AstraZeneca plc — how do they compare? Avient Corporation trades at $45.2 (market cap $4.17B), while AstraZeneca plc trades at $158.61 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 59.5× Avient Corporation's market cap, and Avient Corporation pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| AVNT | AZN | |
|---|---|---|
Market Cap | $4.17B | $248.14B |
Sector | Technology | Health |
52-Week High | $45.69 | $209.48 |
52-Week Low | $27.48 | $147.06 |
Enterprise Value | $5.62B | $275.41B |
Dividend Yield | 2.42% | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVNT trades at $45.33, down 0.7% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported strong Q2 2026 earnings of $0.96 per share, beating estimates, and raised full-year guidance. Revenue growth of 5.8% to $917 million reflects robust demand and operational efficiency. Analysts maintain a buy consensus with a $49.00 price target, citing momentum and value metrics.
Outlook is positive due to consistent earnings beats and dividend payments, but risks include high valuation (P/E 24.55) and potential margin pressure from input costs. Investors should monitor Q3 2026 results against the $0.79 EPS estimate for sustained growth confirmation.
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
